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Abstract
Background: Local tolerance of topical glaucoma treatment is important to achieve a good
compliance. The aim of this study was to evaluate the consequences of local anti-glaucoma drug
side effects on the vision-related quality of life (QoL).
Methods: A mail survey was sent to 20,000 homes of a panel representative of the French
population asking whether one member of the family was suffering from ocular hypertension
(OHT) or glaucoma. (POAG) A computer-assisted telephone interviewing system was used to
confirm self-reported glaucoma, to describe the disease and its treatment, and medical item
consumption. Vision-related QoL was assessed with the NEI-VFQ-25 (National Eye Institute Visual
– Function Questionnaire) and local tolerance with the COMTOL (Comparison of Ophthalmic
Medications for TOLerability).
Results: 13,352 homes (66.7%) answered the mail. 581 people declared they were suffering from
glaucoma or OHT. Prevalence was 1.8%, increasing with age. 204 patients were selected at random
Their NEI-VFQ-25 global score showed an overall good QoL. Two domain scores showed some
deterioration: general health and driving. 62.4% of the patients cited at least one local side effect.
25.4% had burning, 20.8% blurred vision and 20.2% tearing. Poor vision related QoL was associated
with the presence of local side effects leading to poor perceived treatment satisfaction. Dissatisfied
patients visited their ophthalmologist more frequently.
Conclusion: Based on a representative French sample, poor vision related QoL was associated
with topical drug side effects that also impact patient satisfaction and compliance. Longitudinal data
collection should be performed to confirm our findings.
Background
Primary open-angle Glaucoma (POAG) is characterised
by a progressive alteration of the optic nerve. Glaucoma is
one of the three leading causes of blindness in developed
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countries along with cataract and age-related macular
degeneration [1]. Prevalence varies between 1% and 4%
in people over 40 and they increase with age [2-12]. Risk
factor analyses found a higher intra-ocular pressure (IOP)
[13-18] although all patients with ocular hypertension
(OHT) will not develop POAG [19].
Control of IOP is one of the critical items of glaucoma pre-
vention in the >40 old population. Several medical strate-
gies have been developed to reach this objective including
drugs, laser and surgery. Choice of glaucoma therapy
involves patient characteristics, clinical history, and co-
morbidity [20,21] but also the likely effectiveness of an
agent, the side effect profile [22], comfort upon adminis-
tration, and the daily frequency of administration.
Topical treatment aimed at decreasing IOP is for the
whole life of patients [23,24]. Compliance is of major
importance [25] to get the full potential protective effect
against visual field defect. Therefore, tolerance of topical
treatment is a critical issue.
Odberg [23,24] demonstrated that the QoL of patients
was affected at the time of the diagnosis announce,
although no strong relationship was found between visual
field disability and vision related QoL. This correlation
was also confirmed in the Collaborative Initial Glaucoma
Treatment [25,26] and other studies [27-31]. Most of QoL
evaluation in glaucoma was measured in clinical trial set-
ting [32-38] showing small differences between the alter-
natives that reached very rarely the statistical significance.
The link between QoL and patient-reported side effect of
topical treatment has been very rarely studied. Wandell
[39] found that beta-blockers with or without miotic
agent had no negative impact on health related quality of
life using a generic quality of life instrument. Barber
[40,41] developed a dedicated instrument (The COM-
TOL: Comparison of ophthalmic medications for tolera-
bility) aimed at measuring the QoL consequences of
topical adverse events.
The aim of this study was to evaluate the relationship
between vision-related quality of life and local side effects
on a representative French sample of glaucoma patients
treated with a topical anti-glaucoma drug who were con-
tacted outside of any medical environment.
Methods
The survey was performed according to the French Law.
The aim of the study was explained to the subjects before
starting the questionnaire and they were asked whether
they would accept to participate. The Sofres panel was
expected to meet the objective of being representative of
the French population and therefore by questioning on
their medical treatment to get a sample representative of
French patients treated for OHT / POAG. This panel is
made up of 20,000 households (53,000 people) stratified
by geographic area, city size, resident age, social and pro-
fessional clusters and number of people within the house-
hold. Quotas were determined according to the results of
the national census survey [42] with an average pick-up
rate of 1/1000 done at two levels: 69 strata for the house-
holds and 114 strata for the individuals. Selected house-
holds were expected to stay in the panel for 4 years.
Household replacements followed the same quota rules.
Yearly renewal rate was 27%. For the last 10 years, the
response rate with medical questionnaire used to be
between 70 to 80% [43-46].
A mail survey was sent to all the households of the panel
to identify those in which one resident was suffering from
OHT or glaucoma (diagnosed by a practitioner). A Com-
puter Assisted Telephone Interviewing (CATI) system was
used to collect information on a random sample (patient
Id generated by computer) of households having
answered positively to the previous question. This system
allowed remote data entry while querying and the per-
formance of on-line data consistency checks.
With 200 patients we had 95% chance to capture at least
one patient-reported side effects whose incidence was
higher than 1.5%. Lastly, according to Mangione [47],
alpha being fixed at 5% and beta at 20%, 69 patients per
group were sufficient to show a difference of 10 points on
the global score.
Socio-demographics and glaucoma history were recorded.
The National Eye Institute Visual Function Questionnaire
[48,49] was selected since its 51-item release demon-
strated to be a reliable and valid tool for group-level com-
parisons of vision-targeted, health-related quality of life in
clinical research. The short-form (NEI-VFQ-25) [50] was
selected since its reliability and validity was found compa-
rable to the 51-items. A French validated [51] of the NEI-
VFQ-25 administered by phone interview was used. Anti-
glaucoma treatments were identified based on the citation
of a Rx brand name sold in France [52]: the list of all
brand names available on the French market were cited to
the patients. Since anti-glaucoma generics representing
less than 2% of the market, the INN (International Non-
Proprietary Name) list were not cited [53]. Special atten-
tion was given to the current treatment (name, dosage,
combination, duration, etc...) but also to the previous
treatment, if any, and reasons for change. The COM-TOL
[40,41] was used to assess the local side effects of the cur-
rent topical treatment. At the conclusion of the interview,
global treatment satisfaction (a 6-level answer from very
satisfied to very unsatisfied) was assessed. Compliance
was assessed with the following question: "In the two lastHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/75
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weeks, how many times have you missed your eye drops ?
Possible answers were: never, rarely, some time, rather
often, often, almost always, always missed. Other medical
items included the number of visits to ophthalmologists,
dedicated to glaucoma exams and workdays lost.
Analysis was performed using SAS Software (release 6.12)
and SPAD (release 5.0). The analysis was conducted on
the subset of patients treated with a topical anti-glaucoma
treatment. NEI-VFQ-25 scores were calculated according
to the instrument author's algorithm.
A multi-factorial correspondence analysis [54-56] was
performed to study the relationship between vision-
related quality of life, patient-reported side effects, com-
pliance and treatment satisfaction. The Burt table was
made of the 25 questions of NEI-VFQ-25. Patient-
reported side effects, compliance and treatment satisfac-
tion were considered as supplementary variable. Missing
data were considered as a specific modality for each item.
Chi-square was the used distance.
Comparisons between patients with and without side
effects were performed using an analysis of variance. In
case of variables that could confound the QoL results,
adjustment was made using linear model according to the
least square method. Confidence intervals were calcu-
lated, two-sided, at 95%. Since several statistical tests were
performed when analysing the links between QoL and
patient-reported side effects, a test was considered as sta-
tistically significant if p < 0.001 to keep the global type I
error at 5%.
Results
In December 2000, the survey was sent to 20.000 homes
belonging to the Sofres panel. 13,352 homes answered
the mail (66.7%) corresponding to 32,685 people. 581
patients indicated they had a glaucoma or an OHT diag-
nosed by a practitioner, 564 being older than 40. This
leads to a glaucoma / OHT prevalence of 1.8%. This rate
increased with age from 1.1% (40 to 49 years old) to 8.4%
(>80 years old). No statistical difference was found
between geographical areas of France (from 1.4% to
2.3%).
In February 2001, a sample of 204 people was picked up
at random (random patient Id was generated by compu-
ter) and queried by phone. The questionnaire required 20
to 30 minutes to be completed. 31 patients were not que-
ried since they declared they did not take a topical treat-
ment the day of the interview. 173 patients indicated they
were taking at least one topical treatment at the time of the
interview. 48.5% were males and the mean age was 70
years. 20.2% lived in the countryside, 28.3% in cities over
100.000 inhabitants and 16.8% in the Paris area. Median
monthly household revenue was around EUR 2000 and
15% had a paid professional activity.
Glaucoma / OHT was diagnosed 9.4 years before the inter-
view on average. Mean current topical treatment duration
was 5.9 years and 47% had already changed their treat-
ment at least once, mainly due to lack of efficacy (54.9%)
or intolerance (35.2%). 74.6% of the patients declared
that they never forgot their dose. A topical combination
was prescribed for 28.9%. 69.4% of the patients had a
beta-blocker, 5.2% a miotic, 6.4% an alpha2 agonist,
20.2% a carbonic anhydrase inhibitor, 19.7% a prostag-
landin, and 10.4% a treatment from another class. 89.9%
of the patients declared they were satisfied or very satisfied
with the treatment. 92.4% of the patients declared they
were "satisfied" or "very satisfied" with the way their dis-
ease was managed. The average number of visits to the
ophthalmologist to care for a glaucoma / OHT patient was
2.35 per year.
Figure 1 illustrates the prevalence of each individual side
effect as reported by the COM-TOL. 37.6% had no side
effects, 24.9% had one, 11.6% had 2, 7.0% had 3, and
18.9% had 4 and more. Three side effects were reported by
more than 20% of the patients: burning (25.4%), blurred
vision (20.8%) and tearing (20.2%) were mentioned
most often. Patients with and without patient-reported
side effects were found comparable on all socio-demo-
graphics and glaucoma history parameters with the excep-
tion of gender: females declared more patient-reported
side effects (70.2% versus 55.1%; P < 0.04).
Figure 2 shows the average (+/- standard deviation) scores
on each domain of the NEI-VFQ-25. All scores were
higher than 50 except the general health score. All vision
related scores were higher than 70 and the general vision
score was the lowest of the vision-related scores. Some
scores were found statistically higher in men: global,
vision, near vision, distance vision, mental, role and
driving.
Table 1 (see Additional file: 1) shows QoL scores differ-
ence (with 95% confidence limit) between patients with
and without an patient-reported side effect (adjusted for
gender).
Before adjustment for test multiplicity, four dimensions
of the NEI-VFQ-25 were strongly associated with side
effects: Ocular pain (11 events), Mental health (10
events), Global (10 events) and Dependency (8 events).
Six side effects were associated with more than half of the
13 dimensions of NEI-VFQ-25: Trouble seeing at night
(11 scores), Dimming of vision (10), Dry eyes (9), Read-
ing trouble (8), Burning / stinging in the eyes (7) and Dif-
ficulty in focusing from near to far (7). The decrease inHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/75
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quality of life varied from 5.6 (tearing) to 31.2% (troubles
seeing at night side effect on driving score).
After adjustment for test multiplicity, the global score was
affected by Burning, Dimming of vision, Reading and
Trouble seeing at night. Ocular pain was associated with
Burning, Itchy eyes and Redness. Near vision was associ-
ated with Dimming of vision, Mental health with Burn-
ing, Dimming of vision, Focusing and Troubles seeing at
night. Lastly, Dependency and Driving were affected by
Troubles seeing at night
Figure 3 describes the results of the multiple factorial cor-
respondence analysis. Only the graph with axes 1 and 2
was presented since it supports the biggest part of the
information. Missing values did not contribute to the QoL
information. Axis one involved vision-related QoL: the
more positive the value, the greater the negative conse-
quences on vision related quality of life. Axis 2 involved
QoL social consequences: the lower the number the
greater the QoL social consequences.
Brow-ache, Dimming of vision, Trouble seeing at night,
Dry eyes, Dimming of vision, Trouble reading and Diffi-
culty at focusing were the side effects that decreased the
most on vision related QoL while unusual taste was the
item having the least consequence. Brow-ache was the
item perceived as having consequences on Social QoL in
opposition to dry eye. It appeared that there was a strong
relationship between QoL and treatment satisfaction:
"rather unsatisfied" patients and "unsatisfied" patients
had worse vision related QoL than the "satisfied" patients.
Patients having bad QoL (axis 1) and social consequences
(axis 2) were those who were the least compliant and
unsatisfied towards their treatment.
Patient satisfaction was linked to number of visits to the
ophthalmologist (P < 0.01): patients who were "rather
Side effect prevalence according to the COM-TOL checklist Figure 1
Side effect prevalence according to the COM-TOL checklist.
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satisfied" or more visited an ophthalmologist 2.27 per
year against 3.50 for the unsatisfied patients.
Discussion
The use of the Sofres panel allowed us to reach one of our
major objectives: to get a representative sample of patients
being treated with a glaucoma drug. We had the expected
response rate (66.7% is close to the usual 70% observed
with our panel) to the mail sent to the households. The
socio-demographics characteristics of responders were
not different from the non-responders. Moreover, these
characteristics were close to the nation-wide INSEE (Insti-
tut National de la Statistique et des Etudes Economiques)
survey [42], suggesting no major selection bias. The way
we captured patients was based on the diagnosis made by
a practitioner, which is the most obvious information for
a patient treated for a chronic condition. The prescription
frequencies of anti-glaucomatous drugs estimated in our
study were close to those observed in IMS (International
Medical Statistics) data [53] and prevalence figures were
close to the literature [2-12]. In no way does this study
allow one to conclude that French patients were correctly
treated on a national basis but resources dedicated to
glaucoma treatment / prevention are in accordance to
international literature prevalence estimates.
This was a cross-sectional survey and this study was lim-
ited to the link between patient-reported side effects and
vision-related quality of life. Longitudinal data collection
should be performed to confirm the causality of the
relationship.
The use of patient phone interview was chosen in order to
avoid medical interactions and to collect information as
perceived by the patients. Although we did not cross check
the collected information with medical records, it
appeared that regardless of treatment duration, two-thirds
of the patients had side effects. Of course, systematic que-
ries might lead to overestimating side effect rates resulting
in an observational bias. In any case, according to this
NEI-VFQ-25 average score (standard deviation) Figure 2
NEI-VFQ-25 average score (standard deviation). 0: worst quality of life; 100 highest quality of life.
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survey, these side effects were associated with lower
patient vision related QoL. Being in a non-medical envi-
ronment, we were not able to collect hard medical infor-
mation. Therefore, we were not able to confirm the
disease (POAG versus OHT) and QoL could not be
adjusted for co-morbidity (for example cataracts, macular
degeneration). Neither we had a confirmation of medical
therapy or compliance. However, we found no differences
between patients with and without patient-reported side
effects on all the collected variables with the exception of
gender. Of course, we were not able to check the group
comparability on the medical parameters and therefore
we were not able to adjust for any potential bias There-
fore, we decided to adjust our QoL estimates on gender.
Moreover, since we focused mainly on local side effects
and vision related QoL, the effect of co-morbidity on
vision-specific QoL should be less than if QoL data were
collected with a generic instrument. Lastly, the use of a
vision-specific QoL instrument, which should be more
sensitive than a generic one, allowed us to find some rela-
tionships with side effects, somewhat in contradiction
with Wandell [39].
Some association was found between patient satisfaction
and quality of life. This could, at least partially, be
explained by factors we were not able to collect. Moreover,
Multiple Factorial Correspondence Analysis Figure 3
Multiple Factorial Correspondence Analysis. Distance used: Chi-square. Axis 1 (QOL global score) by Axis 2 (Social Conse-
quences). Active variables (the one that determined the structure and the identification of the axes) were the 25 items of the 
NEI-VFQ-25; they were not presented in this graph to improve readability. Illustrative variables (the one that allowed to iden-
tify patient sub-groups) consisted in side effect list of COM-TOL, compliance. Axis 1 estimated the intensity of QoL a global 
unique score: negative values were associated with 'Good QoL' while positive values were associated with 'Poor QoL'. Nega-
tive values on Axis 2 were associated with 'Bad social QoL'. Points, which were close, were highly correlated while points, 
which were far, were independent.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/75
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the reasons of the visits to the ophthalmologist were not
documented and we don't know whether it was associated
with poor medication control or vision function loss, etc
...
We did not calculate the QoL score from the COMTOL
since, as a very glaucoma-specific QoL instrument (i.e.
dedicated to side effects in glaucoma / OHT treatment), it
does not allow to estimate the usual dimensions of QoL,
like mental, social, general health, etc.. This is why we
used the COMTOL only to list local side effects and the
NEI-VFQ-25 to get their effects on QoL.
Trouble seeing at night, Dimming of vision, Trouble read-
ing and Difficulty at focusing from near to far were con-
sistently associated with poor vision related QoL. The
differences observed between patients with and without
these patient-reported side effects were comparable to the
ones described by Mangione between patients with glau-
coma and control case [49]. Drawing a conclusion from
Brow-ache and Dry eye is difficult due to the too few
patients having experienced these events.
The quality of life of patients was globally high (>70) on
most of the dimensions, excepted general health. This
might reflect the QoL of an old population living in the
community with only few of them presenting severe vis-
ual field defect, although the absence of a control group in
our survey does not allow a direct measure of the medical
significance of our findings. Therefore, avoiding topical
drug side effects should be a major concern to maintain
this high QoL level. However, our general health domain
score is lower than the one in Mangione [48,49]. In the
latter, QoL data were collected in the front of an ophthal-
mologist, leading to some observational bias. Our popu-
lation was older. Lastly, their sample was not taken at
random. Unfortunately, in our study, declarative co-mor-
bidity and concomitant medications were not collected
since we did not want the phone interview duration to
exceed 30 minutes per subject.
Questioning patient on compliance during a visit to an
ophthalmologist is often a very difficult issue, since there
is no objective way to measure it. We found 4 patient-
reported side effects that were associated with poor vision-
related QoL: trouble seeing at night, trouble reading, dim-
ming of vision and difficulty at focusing. We also found
an association between compliance (patients often
missed their drop) and poor quality of life. Our findings
suggest that patients presenting with one of these 4
patient-reported side effects should be queried into details
in order to capture lack of compliance and, if requested,
to switch to a drug which is more tolerable.
Conclusion
In our survey, vision related QoL of French patients with
topical anti-glaucomatous drug side effects has been
found lower, with poor treatment satisfaction and addi-
tional visits to the ophthalmologist. Further longitudinal
data collection should be collected to confirm our
findings.
Authors' contributions
JPN was in charge of the medical expertise and contrib-
uted to the writing of the paper.
NA and SR participated in the design of the study and car-
ried out data collection.
GB conceived the study and participated in its design and
co-ordination.
All authors read and approved the final manuscript.
Additional material
Acknowledgement
The survey was supported by an unrestricted grant from Alcon Laborato-
ries SA, Rueil-Malmaison, France, was conducted according to the local 
laws, and was contracted to Taylor Nelson Sofrès Santé, Montrouge, 
France.
References
1. Goldstein H: Magnitude and causes of blindness : Sources and
limitations of data. In clinical ophthalmology  Volume 5. Issue 52
Edited by: Freemann JS.  Lippincott Company, Philadelphia, The USA;
1990:1-10. 
2. Mitchell P, Smith W, Attebo K, Healey PR: Prevalence of open-
angle glaucoma in Australia. The Blue Mountains eye study.
Ophthalmology 1996, 103:1661-9.
3. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J,
Menage MJ: Prevalence of glaucoma. The Beaver Dam Eye
study,. Ophthalmology 1992, 99:1499-1504.
4. Ekstrom C: Prevalence of open-angle glaucoma in central
Sweden. The Tierp glaucoma survey.  Acta Ophthalmologica
Scandinavica 1996, 74:107-12.
5. Bengtsonn B: The prevalence of glaucoma.  British Journal
ofOphthalmology 1981, 65:46-9.
6. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson
RS, Dawber TR: The Framingham eye study. I. Outline and
major prevalence findings. II. Associations of ophthalmic
pathology with single variables previously measured in the
Framingham Heart Study. American Journal of Epidemiology 1977,
106:33-41.
7. Kahn HA, Milton RC: Alternative definitions of open angle glau-
coma. Effects on prevalence and associations in the Framing-
ham Eye Study. Archives of Ophthalmology 1980, 98:2172-7.
Additional file 1
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7525-1-75-S1.doc]Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/75
Page 8 of 9
(page number not for citation purposes)
8. Kahn HA, Milton RC: Revised Framingham eye study preva-
lence of glaucoma and diabetic retinopathy. American Journal of
Epidemiology 1980, 111:769-76.
9. Martinez GS, Campbell AJ, Reinken J, Allan BC: Prevalence of ocu-
lar disease in population 65 years old and older. American Jour-
nal of Ophthalmology 1982, 94:181-189.
10. Podgor MJ, Leske MC, Ederer F: Incidence estimates for lens
changes, macular changes, open-angle glaucoma and dia-
betic retinopathy.  American Journal of Epidemiology 1983,
118:206-212.
11. Tuck MW, Crick RP: The age distribution of primary open
angle glaucoma. Ophthalmic Epidemiology 1998, 5:173-183.
12. Quigley HA, Vitale S: Models of open-angle glaucoma preva-
lence and incidence in the United States. Investigative Ophthal-
mology and Visual Science 1997, 38:83-91.
13. Armaly MF: Ocular pressure and visual fields : A ten-year fol-
low-up study. Arch Ophthalmol 1969, 81:25-44.
14. Rota-Bartelink AM, Pitt A, Story I: Influence of diurnal variation
on the intraocular pressure measurement of treated pri-
mary open-angle glaucoma during office hours.  J Glaucoma
1996, 5(6):410-5.
15. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K:
Large diurnal fluctuations in intraocular pressure are an
independent risk factor in patients with glaucoma. J Glaucoma
2000, 9(2):134-42.
16. Gonzalez I, Pablo LE, Pueyo M, Ferrer E, Melcon B, Abecia E, Honru-
bia FM: Assessment of diurnal tensional curve in early glau-
coma damage. Int Ophthalmol 1997, 20(1–3):113-5.
17. Zeimer RC, Wilensky JT, Gieser DK, Viana MAG: Association
between intra-ocular pressure peaks and progression of vis-
ual field loss. Ophthalmology 1991, 98(1):64-69.
18. The AGIS investigators: The advanced glaucoma intervention
study (AGIS) : 7. The relationship between control of intra-
ocular pressure and visual field deterioration. American Journal
of Ophthalmology 2000, 130(4):429-440.
19. Kitazawa Y, Horie T, Aoki S: Untreated ocular hypertension. A
long-term prospective study.  Arch Ophthalmol 1977,
95:1180-1189.
20. Anderson DR: The management of elevated intraocular pres-
sure with normal optic discs and visual fields. Surv Ophthalmol
1977, 21:479-89.
21. Fingeret M: Glaucoma medications, glaucoma therapy, and
the evolving paradigm. J Am Optom Assoc 1998, 69(2):115-21.
22. Reyes E, Izquierdo NJ, Blasini M: Adverse drugs reactions associ-
ated with glaucoma medications. Bol Asoc Med P R 1997, 89(4–
6):51-5.
23. Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glau-
coma on the quality of life of patients in Norway. II. Patient
response correlated to objective data.  Acta Ophthalmologica
Scandinavica 2001, 79:121-4.
24. Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glau-
coma on the quality of life of patients in Norway. I. Results
from a self-administered questionnaire. Acta Ophthalmologica
Scandinavica 2001, 79:116-20.
25. Mills RP, Janz NK, Wren PA, Guire KE: Correlation of visual field
with quality-of-life measures at diagnosis in the Collabora-
tive Initial Glaucoma Treatment Study (CIGTS). Journal of
Glaucoma 2001, 10:192-198.
26. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE:
Quality of life in newly diagnosed glaucoma patients : The
collaborative Initial Glaucoma Treatment Study. Ophthalmol-
ogy 2001, 108:887-97.
27. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF,
McGorray S: Glaucoma's impact on quality of life and its rela-
tion to clinical indicators. A pilot study. Ophthalmology 1998,
105:561-6.
28. Mills RP: Correlation of quality of life with clinical symptoms
and signs at the time of glaucoma diagnosis. Transactions of the
American Ophthalmological Society 1998, 96:753-812.
29. Parrish RK, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC, Mangione
CM, Montenegro-Piniella A: Visual function and quality of life
among patients with glaucoma. Archives of Ophthalmology 1997,
115:1447-55.
30. Parrish RK: Visual impairment, visual functioning, and quality
of life assessments in patients with glaucoma. Transactions of
the American Ophthalmological Society 1996, 94:919-1028.
31. Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, Win J, Lai
A: Functional status and well being in patients with glaucoma
as measured by the Medical Outcomes Study Short Form-36
questionnaire. Ophthalmology 1998, 105:2112-6.
32. Marchetti A, Magar R, An P, Nichol M: Clinical and economic
impact of new trends in glaucoma treatment.  MedGenMed
[serial online] 2001, 3:6.
33. Cantor LB, Hoop J, Katz LJ, Flartey K, Alphagan/Betaxol Clinical Study
Group: Comparison of the clinical success and quality-of-life
impact of brimonidine 0.2% and betaxolol 0.25 % suspension
in patients with elevated intraocular pressure. Clin Ther 2001,
23:1032-9.
34. Javitt JC, Schiffman RM: Clinical success and quality of life with
brimonidine 0.2% or timolol 0.5% used twice daily in glau-
coma or ocular hypertension: a randomized clinical trial.
Brimonidine Outcomes Study Group I.  Journal of Glaucoma
2000, 9:224-34.
35. Javitt J, Goldberg I: Comparison of the clinical success rates and
quality of life effects of brimonidine tartrate 0.2% and betax-
olol 0.25% suspension in patients with open-angle glaucoma
and ocular hypertension. Brimonidine Outcomes Study
Group II. Journal of Glaucoma 2000, 9:398-408.
36. Lee DA, Gornbein JA: Effectiveness and safety of brimonidine
as adjunctive therapy for patients with elevated intraocular
pressure in a large, open-label community trial.  Journal of
Glaucoma 2001, 10:220-6.
37. Strohmaier K, Snyder E, Adamsons I: A multicenter study com-
paring dorzolamide and pilocarpine as adjunctive therapy to
timolol: patient preference and impact on daily life. Journal of
the American Optometric Association 1998, 69:441-51.
38. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R,
Sherwood M, Meng K, Mangione CM: Influence of glaucomatous
visual field loss on health-related quality of life. Arch Ophthalmol
1997, 115:777-84.
39. Wandell PE, Lundstrom M, Brorsson B, Aberg H: Quality of life
among patients with glaucoma in Sweden.  Acta Ophthalmol
Scand 1997, 75:584-8.
40. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA: Valida-
tion of a questionnaire for comparing the tolerability of oph-
thalmic medications. Ophthalmology 1997, 104:334-42.
41. Barber BL, Santanello NC: Relating spontaneous adverse expe-
rience reports to scores on a questionnaire querying
tolerability.  International Journal of Clinical Pharmacology and
Therapeutics 1995, 33:598-604.
42. INSEE 2000 [http://www.insee.fr/].
43. Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: Etude
pharmaco-épidémiologique de la consommation des antidé-
presseurs en population générale. L'Encéphale 1996, Sp I.:39-48.
44. Frexinos J, Denis P, Allemand H, Allouche S, Los F, Bonnelye G:
Etude descriptive des symptômes fonctionnels digestifs dans
la population générale française.  Gastroenterol Clin Biol 1998,
22:785-91.
45. Antona D, Guérin N: Couverture vaccinale rougeole – rubéole
– oreillons en France en 1998 : première et deuxième doses.
BEH 1999, 19:74-5.
46. Le Pen C, Levy E: Socio-économie de la maladie veineuse : les
enseignements d'une enquête sur les consommateurs de
médicaments phlébotoniques en France.  Phlébologie 1993,
46(n°1):47-63.
47. Mangione CM: The National Eye Institute 25-item Visual Func-
tion, Questionnaire (VFQ-25) – Scoring algorithm. 2000:1-15.
48. Mangione CM, Berry S, Spritzer K, Kanz NK, Klein R, Owsley C, LPP
: Identifying the content area for the 51-item National Eye
Institute Visual Function Questionnaire: results from focus
groups with visually impaired persons. Archives of Ophthalmology
1998, 116:227-33.
49. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD: Psycho-
metric properties of the National Eye Institute Visual Func-
tion Questionnaire (NEI-VFQ). NEI-VFQ Field Test
Investigators. Archives of Ophthalmology 1998, 116:1496-504.
50. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RI,
National Eye Institute Visual Function Questionnaire Field Test Inves-
tigators: Development of the 25-item National Eye Institute
Visual Function Questionnaire. Archives of Ophthalmology 2001,
119(7):1050-1058.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/75
Page 9 of 9
(page number not for citation purposes)
51. Nordmann JP, Sullivan K, Viala M, Arnoult B, Berdeaux G: Psycho-
metric validation of the NEI-VFQ 25 French version in a pop-
ulation of patients treated for ocular hypertension and
glaucoma. PharmacoEconomics  in press.
52. Vidal. Ed du Vidal, Paris 2001.
53. International Medical Statistics, Paris 2001.
54. Guttman L: The qualification of a class of attributes: a theory
and method of a scale construction. In: The Prediction of Personal
Adjustment Edited by: Horst P. New York: SSCR; 1941:251-264. 
55. Burt C: The factorial analysis of qualitative data. British Journal
of Statistical Psychology 1950, 3:166-185.
56. Hayashi C: Theory and examples of quantification (II). Proceed-
ings of the Institute of Statistics and Mathematics 1956, 4:19-30.